Empagliflozin significantly attenuates sotalol-induced QTc prolongation in rats.

Creative Commons License

Barış V., Dinçsoy B., Gedikli E., Erdemb A.

Kardiologia polska, cilt.79, ss.53-57, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 79
  • Basım Tarihi: 2021
  • Doi Numarası: 10.33963/kp.15666
  • Dergi Adı: Kardiologia polska
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.53-57
  • Anahtar Kelimeler: empagliflozin, sotalol, QTc prolongation, HEART-FAILURE, RISK, MORTALITY, DISEASE
  • Hacettepe Üniversitesi Adresli: Evet

Özet

BACKGROUND Sotalol is a class III antiarrhythmic drug commonly used in various arrhythmia treatments. However, due to its potent potassium channel inhibition, it can prolong the QT interval and lead to malignant arrhythmias. Empagliflozin is an inhibitor of sodium-glucose cotransporter 2 (SGLT2) and has a positive effect on cardiovascular outcomes. Since the effect of empagliflozin on the activation of potassium channels is unknown, there is no recommendation regarding the coadministration of these drugs.